Precision Microbiome Testing

Single-nucleotide resolution for clinical & commercial applications

REMANALYTICS

REM Analytics 2026

Challenge

Microbiome-based products face a precision gap: standard methods lack the resolution needed for regulatory claims and product differentiation.

Many biomarkers require distinguishing between closely related species. Without this, claims lack supporting evidence.

Species and strain-level precision for validated claims and faster market approval.

Clinical Evidence

Clinical validation demonstrates clear group separation using species-level profiling:



Fertility outcome prediction: Validated biomarkers predict IVF success



Autism & ADHD prediction: Early biomarkers for developmental screening

Our Approach:

ATGC platform

Proprietary Cycling Temperature Capillary Electrophoresis (CTCE) for single-nucleotide resolution.
Patent pending.

Powered by Cello
96-capillary system

Applications

Women's Health

- IVF outcome prediction
- Recurrent infection risk (Candida, BV, UTI)
- Hormone therapy monitoring

CE-IVD marked

Gut Microbiome

- Bifidobacterium subspecies profiling
- Probiotic strain QC
- Infant microbiome development

Validated in 500+ samples

Soil & Agriculture

- Soil health profiling
- Bioinoculant validation & QC
- Rhizosphere analysis

3 active Horizon Europe projects

Services & Partnership Opportunities

Clinical Studies
End-to-end trial management
Evidence for claims & approval
Lower cost per participant

Research Collaboration
Microbiome as study endpoint
Shared publications & IP
Data that supports product claims

Custom Assay Development
Your specific targets
Rapid design process
Regulatory-ready validation

Tell us your biomarker challenge — we'll design the assay that makes it possible

info@remanalytics.ch
BioArk, Monthey (VS)

www.remanalytics.ch
From challenge to market — your microbiome partner

Member Swiss Biotech Association